Targretin is a cancer medicine used for the treatment of the visible signs on the skin of cutaneous T-cell lymphoma (CTCL). CTCL is a rare type of lymphoma (cancer of the lymph tissue) where some white blood cells (T-cells) grow in the skin. Targretin is used in patients who have an advanced disease and have had at least one other treatment.
Therapeutic Indication
### Therapeutic indication Targretin capsules are indicated for the treatment of skin manifestations of advanced stage cutaneous T-cell lymphoma (CTCL) patients refractory to at least one systemic treatment.
Therapeutic Area (MeSH)
N/AATC Code
L01XF03
ATC Item
bexarotene
Pharmacotherapeutic Group
Antineoplastic agents
Active Substance (Summary)
INN / Common Names
N/A| Substance | CAS | Monograph |
|---|---|---|
| bexarotene | N/A | 白沙罗汀 |
EMA Name
Targretin
Medicine Name
Targretin
Aliases
N/ANo risk management plan link.
